RU2007126761A - ПРОИЗВОДНЫЕ ПИРРОЛА, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К РЕЦЕПТОРУ CRTh2 - Google Patents
ПРОИЗВОДНЫЕ ПИРРОЛА, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К РЕЦЕПТОРУ CRTh2 Download PDFInfo
- Publication number
- RU2007126761A RU2007126761A RU2007126761/04A RU2007126761A RU2007126761A RU 2007126761 A RU2007126761 A RU 2007126761A RU 2007126761/04 A RU2007126761/04 A RU 2007126761/04A RU 2007126761 A RU2007126761 A RU 2007126761A RU 2007126761 A RU2007126761 A RU 2007126761A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- group
- acetic acid
- cyano
- pyrrol
- Prior art date
Links
- 102000009389 Prostaglandin D receptors Human genes 0.000 title 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 title 1
- 230000003042 antagnostic effect Effects 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 36
- 125000000623 heterocyclic group Chemical group 0.000 claims 23
- 229910052799 carbon Inorganic materials 0.000 claims 22
- 229910052757 nitrogen Inorganic materials 0.000 claims 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 20
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 125000005842 heteroatom Chemical group 0.000 claims 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 18
- 229910052717 sulfur Inorganic materials 0.000 claims 18
- 239000011593 sulfur Substances 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 16
- 229910052760 oxygen Inorganic materials 0.000 claims 16
- 239000001301 oxygen Substances 0.000 claims 16
- -1 amino, amino Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 239000012458 free base Substances 0.000 claims 7
- 125000001188 haloalkyl group Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims 6
- 125000002837 carbocyclic group Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- YJUVYHOMALZUHD-UHFFFAOYSA-N 2-(3-cyano-4-phenylpyrrol-1-yl)acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C=CC=CC=2)=C1 YJUVYHOMALZUHD-UHFFFAOYSA-N 0.000 claims 1
- PTNSYGUCCHMLFH-UHFFFAOYSA-N 2-[3-(1,3-benzodioxol-4-yl)-4-cyanopyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C=3OCOC=3C=CC=2)=C1 PTNSYGUCCHMLFH-UHFFFAOYSA-N 0.000 claims 1
- KVANDVBZBOFONL-UHFFFAOYSA-N 2-[3-(2-chlorophenyl)-4-cyanopyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C(=CC=CC=2)Cl)=C1 KVANDVBZBOFONL-UHFFFAOYSA-N 0.000 claims 1
- QPSNHFIHNPXEQO-UHFFFAOYSA-N 2-[3-(3-chloro-2-fluorophenyl)-4-cyanopyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C(=C(Cl)C=CC=2)F)=C1 QPSNHFIHNPXEQO-UHFFFAOYSA-N 0.000 claims 1
- UWAMJVIZSDIZQS-UHFFFAOYSA-N 2-[3-(3-chloro-5-cyanophenyl)-4-cyanopyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C=C(C=C(Cl)C=2)C#N)=C1 UWAMJVIZSDIZQS-UHFFFAOYSA-N 0.000 claims 1
- WPTSJPTVHDPOLW-UHFFFAOYSA-N 2-[3-(3-chloro-5-ethylsulfonylphenyl)-4-cyanopyrrol-1-yl]acetic acid Chemical compound CCS(=O)(=O)C1=CC(Cl)=CC(C=2C(=CN(CC(O)=O)C=2)C#N)=C1 WPTSJPTVHDPOLW-UHFFFAOYSA-N 0.000 claims 1
- UVWJVZZLVYDYIB-UHFFFAOYSA-N 2-[3-(3-chloro-5-morpholin-4-ylsulfonylphenyl)-4-cyanopyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C=C(C=C(Cl)C=2)S(=O)(=O)N2CCOCC2)=C1 UVWJVZZLVYDYIB-UHFFFAOYSA-N 0.000 claims 1
- ADSFMGHJXUZFFQ-UHFFFAOYSA-N 2-[3-(3-chloro-5-piperidin-1-ylsulfonylphenyl)-4-cyanopyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C=C(C=C(Cl)C=2)S(=O)(=O)N2CCCCC2)=C1 ADSFMGHJXUZFFQ-UHFFFAOYSA-N 0.000 claims 1
- BMIJYDIIIHBVEZ-UHFFFAOYSA-N 2-[3-(3-chloro-5-pyrrolidin-1-ylsulfonylphenyl)-4-cyanopyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C=C(C=C(Cl)C=2)S(=O)(=O)N2CCCC2)=C1 BMIJYDIIIHBVEZ-UHFFFAOYSA-N 0.000 claims 1
- QREXYXJZFJMYCT-UHFFFAOYSA-N 2-[3-(3-chlorophenyl)-4-cyanopyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C=C(Cl)C=CC=2)=C1 QREXYXJZFJMYCT-UHFFFAOYSA-N 0.000 claims 1
- LRRHUBLNVLGYCO-UHFFFAOYSA-N 2-[3-(4-chlorophenyl)-4-cyanopyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C=CC(Cl)=CC=2)=C1 LRRHUBLNVLGYCO-UHFFFAOYSA-N 0.000 claims 1
- DQSBVIFHCQLGIZ-UHFFFAOYSA-N 2-[3-[2,5-bis(trifluoromethyl)phenyl]-4-cyanopyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C(=CC=C(C=2)C(F)(F)F)C(F)(F)F)=C1 DQSBVIFHCQLGIZ-UHFFFAOYSA-N 0.000 claims 1
- DRAHOOXBWFOGPU-UHFFFAOYSA-N 2-[3-[2-chloro-3-(trifluoromethyl)phenyl]-4-cyanopyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C(=C(C=CC=2)C(F)(F)F)Cl)=C1 DRAHOOXBWFOGPU-UHFFFAOYSA-N 0.000 claims 1
- AKFOWPWOLZROCF-UHFFFAOYSA-N 2-[3-[2-chloro-5-(trifluoromethyl)phenyl]-4-cyanopyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C(=CC=C(C=2)C(F)(F)F)Cl)=C1 AKFOWPWOLZROCF-UHFFFAOYSA-N 0.000 claims 1
- FFBKASIWFMZZLG-UHFFFAOYSA-N 2-[3-[3,5-bis(trifluoromethyl)phenyl]-4-(dimethylcarbamoyl)pyrrol-1-yl]acetic acid Chemical compound CN(C)C(=O)C1=CN(CC(O)=O)C=C1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 FFBKASIWFMZZLG-UHFFFAOYSA-N 0.000 claims 1
- OAFAGCNQKIENPF-UHFFFAOYSA-N 2-[3-[3,5-bis(trifluoromethyl)phenyl]-4-cyanopyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)=C1 OAFAGCNQKIENPF-UHFFFAOYSA-N 0.000 claims 1
- LNGOZLGOFMFFHM-UHFFFAOYSA-N 2-[3-[3,5-bis(trifluoromethyl)phenyl]-4-cyanopyrrol-1-yl]propanoic acid Chemical compound OC(=O)C(C)N1C=C(C#N)C(C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)=C1 LNGOZLGOFMFFHM-UHFFFAOYSA-N 0.000 claims 1
- CHKQKEZYJIJDGD-UHFFFAOYSA-N 2-[3-[3-(butylsulfamoyl)-5-(trifluoromethyl)phenyl]-4-cyanopyrrol-1-yl]acetic acid Chemical compound FC(F)(F)C1=CC(S(=O)(=O)NCCCC)=CC(C=2C(=CN(CC(O)=O)C=2)C#N)=C1 CHKQKEZYJIJDGD-UHFFFAOYSA-N 0.000 claims 1
- ATMOSMKZQQJYJW-UHFFFAOYSA-N 2-[3-[3-[butyl(methyl)sulfamoyl]-5-(trifluoromethyl)phenyl]-4-cyanopyrrol-1-yl]acetic acid Chemical compound FC(F)(F)C1=CC(S(=O)(=O)N(C)CCCC)=CC(C=2C(=CN(CC(O)=O)C=2)C#N)=C1 ATMOSMKZQQJYJW-UHFFFAOYSA-N 0.000 claims 1
- QLVWPNRSAWXSJV-UHFFFAOYSA-N 2-[3-[3-butylsulfonyl-5-(trifluoromethyl)phenyl]-4-cyanopyrrol-1-yl]acetic acid Chemical compound FC(F)(F)C1=CC(S(=O)(=O)CCCC)=CC(C=2C(=CN(CC(O)=O)C=2)C#N)=C1 QLVWPNRSAWXSJV-UHFFFAOYSA-N 0.000 claims 1
- LRNQXCQQIXFMJC-UHFFFAOYSA-N 2-[3-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-4-cyanopyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C(=C(Cl)C=C(C=2)C(F)(F)F)F)=C1 LRNQXCQQIXFMJC-UHFFFAOYSA-N 0.000 claims 1
- VFDPMBJXNWARNK-UHFFFAOYSA-N 2-[3-[3-chloro-5-(trifluoromethyl)phenyl]-4-cyanopyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C=C(C=C(Cl)C=2)C(F)(F)F)=C1 VFDPMBJXNWARNK-UHFFFAOYSA-N 0.000 claims 1
- CGDSGZVQOSTXLM-UHFFFAOYSA-N 2-[3-[3-chloro-5-[2-hydroxyethyl(methyl)sulfamoyl]phenyl]-4-cyanopyrrol-1-yl]acetic acid Chemical compound OCCN(C)S(=O)(=O)C1=CC(Cl)=CC(C=2C(=CN(CC(O)=O)C=2)C#N)=C1 CGDSGZVQOSTXLM-UHFFFAOYSA-N 0.000 claims 1
- PAFIUVAQVSWDKA-UHFFFAOYSA-N 2-[3-[3-chloro-5-[4-(2-cyanoethyl)piperazin-1-yl]sulfonylphenyl]-4-cyanopyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C=C(C=C(Cl)C=2)S(=O)(=O)N2CCN(CCC#N)CC2)=C1 PAFIUVAQVSWDKA-UHFFFAOYSA-N 0.000 claims 1
- FHVUOMXGRCJLHY-UHFFFAOYSA-N 2-[3-cyano-4-(2,3-dichlorophenyl)pyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C(=C(Cl)C=CC=2)Cl)=C1 FHVUOMXGRCJLHY-UHFFFAOYSA-N 0.000 claims 1
- XUQWSVJVBJAPLP-UHFFFAOYSA-N 2-[3-cyano-4-(2,5-dichlorophenyl)pyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C(=CC=C(Cl)C=2)Cl)=C1 XUQWSVJVBJAPLP-UHFFFAOYSA-N 0.000 claims 1
- SMMTWUDQNLDSHP-UHFFFAOYSA-N 2-[3-cyano-4-(2-cyanophenyl)pyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C(=CC=CC=2)C#N)=C1 SMMTWUDQNLDSHP-UHFFFAOYSA-N 0.000 claims 1
- DIQFFWLQMHWDCP-UHFFFAOYSA-N 2-[3-cyano-4-(3,5-dichlorophenyl)pyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C=C(Cl)C=C(Cl)C=2)=C1 DIQFFWLQMHWDCP-UHFFFAOYSA-N 0.000 claims 1
- MOHZDZZHFPLKLJ-UHFFFAOYSA-N 2-[3-cyano-4-(3,5-difluorophenyl)pyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C=C(F)C=C(F)C=2)=C1 MOHZDZZHFPLKLJ-UHFFFAOYSA-N 0.000 claims 1
- KNJQLFWWPBIONI-UHFFFAOYSA-N 2-[3-cyano-4-(3-cyanophenyl)pyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C=C(C=CC=2)C#N)=C1 KNJQLFWWPBIONI-UHFFFAOYSA-N 0.000 claims 1
- XJRCBKQMSIQHSO-UHFFFAOYSA-N 2-[3-cyano-4-(3-fluorophenyl)pyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C=C(F)C=CC=2)=C1 XJRCBKQMSIQHSO-UHFFFAOYSA-N 0.000 claims 1
- YDGCCGPGWJYIHF-UHFFFAOYSA-N 2-[3-cyano-4-(3-methylsulfonylphenyl)pyrrol-1-yl]acetic acid Chemical compound CS(=O)(=O)C1=CC=CC(C=2C(=CN(CC(O)=O)C=2)C#N)=C1 YDGCCGPGWJYIHF-UHFFFAOYSA-N 0.000 claims 1
- JODJYCSNPQUAKK-UHFFFAOYSA-N 2-[3-cyano-4-(4-fluorophenyl)pyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C=CC(F)=CC=2)=C1 JODJYCSNPQUAKK-UHFFFAOYSA-N 0.000 claims 1
- CSVCPBLCHNEISH-UHFFFAOYSA-N 2-[3-cyano-4-[2-(trifluoromethyl)phenyl]pyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C(=CC=CC=2)C(F)(F)F)=C1 CSVCPBLCHNEISH-UHFFFAOYSA-N 0.000 claims 1
- GLSHONRTDYSKQH-UHFFFAOYSA-N 2-[3-cyano-4-[2-fluoro-3-(trifluoromethyl)phenyl]pyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C(=C(C=CC=2)C(F)(F)F)F)=C1 GLSHONRTDYSKQH-UHFFFAOYSA-N 0.000 claims 1
- IYMACIXIPSGPBQ-UHFFFAOYSA-N 2-[3-cyano-4-[3-(2,2-dimethylpropylsulfamoyl)-5-(trifluoromethyl)phenyl]pyrrol-1-yl]acetic acid Chemical compound FC(F)(F)C1=CC(S(=O)(=O)NCC(C)(C)C)=CC(C=2C(=CN(CC(O)=O)C=2)C#N)=C1 IYMACIXIPSGPBQ-UHFFFAOYSA-N 0.000 claims 1
- XCUKWUPHLJGLHH-UHFFFAOYSA-N 2-[3-cyano-4-[3-(4-fluorophenyl)-5-(trifluoromethyl)phenyl]pyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C=C(C=C(C=2)C=2C=CC(F)=CC=2)C(F)(F)F)=C1 XCUKWUPHLJGLHH-UHFFFAOYSA-N 0.000 claims 1
- FIZLDJYRPHMZHQ-UHFFFAOYSA-N 2-[3-cyano-4-[3-(dimethylsulfamoyl)-5-(trifluoromethyl)phenyl]pyrrol-1-yl]acetic acid Chemical compound FC(F)(F)C1=CC(S(=O)(=O)N(C)C)=CC(C=2C(=CN(CC(O)=O)C=2)C#N)=C1 FIZLDJYRPHMZHQ-UHFFFAOYSA-N 0.000 claims 1
- ZKPOAYTYYUIIQI-UHFFFAOYSA-N 2-[3-cyano-4-[3-(trifluoromethyl)phenyl]pyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C=C(C=CC=2)C(F)(F)F)=C1 ZKPOAYTYYUIIQI-UHFFFAOYSA-N 0.000 claims 1
- AWXSHLGXUHELDP-UHFFFAOYSA-N 2-[3-cyano-4-[3-(trifluoromethylsulfanyl)phenyl]pyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C=C(SC(F)(F)F)C=CC=2)=C1 AWXSHLGXUHELDP-UHFFFAOYSA-N 0.000 claims 1
- AWEBWIKQIPVNDD-UHFFFAOYSA-N 2-[3-cyano-4-[3-[ethyl(methyl)sulfamoyl]-5-(trifluoromethyl)phenyl]pyrrol-1-yl]acetic acid Chemical compound FC(F)(F)C1=CC(S(=O)(=O)N(C)CC)=CC(C=2C(=CN(CC(O)=O)C=2)C#N)=C1 AWEBWIKQIPVNDD-UHFFFAOYSA-N 0.000 claims 1
- XKGCUFXVLVDZCC-UHFFFAOYSA-N 2-[3-cyano-4-[3-cyano-5-(trifluoromethyl)phenyl]pyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C=C(C=C(C=2)C#N)C(F)(F)F)=C1 XKGCUFXVLVDZCC-UHFFFAOYSA-N 0.000 claims 1
- KFOAQYZXQGKDJQ-UHFFFAOYSA-N 2-[3-cyano-4-[3-ethylsulfonyl-5-(trifluoromethyl)phenyl]pyrrol-1-yl]acetic acid Chemical compound FC(F)(F)C1=CC(S(=O)(=O)CC)=CC(C=2C(=CN(CC(O)=O)C=2)C#N)=C1 KFOAQYZXQGKDJQ-UHFFFAOYSA-N 0.000 claims 1
- AVFJEAAZFHVNNT-UHFFFAOYSA-N 2-[3-cyano-4-[3-fluoro-5-(trifluoromethyl)phenyl]pyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C=C(C=C(F)C=2)C(F)(F)F)=C1 AVFJEAAZFHVNNT-UHFFFAOYSA-N 0.000 claims 1
- KRSULBRCZUXZAX-UHFFFAOYSA-N 2-[3-cyano-4-[3-iodo-5-(trifluoromethyl)phenyl]pyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C=C(C=C(I)C=2)C(F)(F)F)=C1 KRSULBRCZUXZAX-UHFFFAOYSA-N 0.000 claims 1
- QOWWDOFGCWJVQR-UHFFFAOYSA-N 2-[3-cyano-4-[3-methylsulfonyl-5-(trifluoromethyl)phenyl]pyrrol-1-yl]acetic acid Chemical compound FC(F)(F)C1=CC(S(=O)(=O)C)=CC(C=2C(=CN(CC(O)=O)C=2)C#N)=C1 QOWWDOFGCWJVQR-UHFFFAOYSA-N 0.000 claims 1
- JOEVFESFEJVZRA-UHFFFAOYSA-N 2-[3-cyano-4-[3-morpholin-4-ylsulfonyl-5-(trifluoromethyl)phenyl]pyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C=C(C=C(C=2)C(F)(F)F)S(=O)(=O)N2CCOCC2)=C1 JOEVFESFEJVZRA-UHFFFAOYSA-N 0.000 claims 1
- FNROMQUPSYPNRU-UHFFFAOYSA-N 2-[3-cyano-4-[3-piperidin-1-ylsulfonyl-5-(trifluoromethyl)phenyl]pyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C=C(C=C(C=2)C(F)(F)F)S(=O)(=O)N2CCCCC2)=C1 FNROMQUPSYPNRU-UHFFFAOYSA-N 0.000 claims 1
- GLUOXGPMVZDVFL-UHFFFAOYSA-N 2-[3-cyano-4-[3-pyrrolidin-1-ylsulfonyl-5-(trifluoromethyl)phenyl]pyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C=C(C=C(C=2)C(F)(F)F)S(=O)(=O)N2CCCC2)=C1 GLUOXGPMVZDVFL-UHFFFAOYSA-N 0.000 claims 1
- YWQFHLWUZBVPRP-UHFFFAOYSA-N 2-[3-cyano-4-[4-(trifluoromethyl)phenyl]pyrrol-1-yl]acetic acid Chemical compound OC(=O)CN1C=C(C#N)C(C=2C=CC(=CC=2)C(F)(F)F)=C1 YWQFHLWUZBVPRP-UHFFFAOYSA-N 0.000 claims 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims 1
- PZHHLCQPEDBCLA-UHFFFAOYSA-N 4-[3,5-bis(trifluoromethyl)phenyl]-1-(carboxymethyl)pyrrole-3-carboxylic acid Chemical compound OC(=O)CN1C=C(C(O)=O)C(C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)=C1 PZHHLCQPEDBCLA-UHFFFAOYSA-N 0.000 claims 1
- 240000006394 Sorghum bicolor Species 0.000 claims 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 claims 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 229940124623 antihistamine drug Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000003434 antitussive agent Substances 0.000 claims 1
- 229940124584 antitussives Drugs 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0427381.9 | 2004-12-14 | ||
| GBGB0427381.9A GB0427381D0 (en) | 2004-12-14 | 2004-12-14 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007126761A true RU2007126761A (ru) | 2009-01-27 |
Family
ID=34090028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007126761/04A RU2007126761A (ru) | 2004-12-14 | 2005-12-12 | ПРОИЗВОДНЫЕ ПИРРОЛА, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К РЕЦЕПТОРУ CRTh2 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20100087432A1 (enExample) |
| EP (1) | EP1828172B1 (enExample) |
| JP (1) | JP2008523130A (enExample) |
| KR (1) | KR20070087605A (enExample) |
| CN (1) | CN101072773B (enExample) |
| AR (1) | AR052266A1 (enExample) |
| AT (1) | ATE449772T1 (enExample) |
| AU (1) | AU2005315881C1 (enExample) |
| BR (1) | BRPI0518607A2 (enExample) |
| CA (1) | CA2587934A1 (enExample) |
| DE (1) | DE602005017935D1 (enExample) |
| ES (1) | ES2335519T3 (enExample) |
| GB (1) | GB0427381D0 (enExample) |
| GT (1) | GT200500360A (enExample) |
| MX (1) | MX2007007098A (enExample) |
| PE (1) | PE20060736A1 (enExample) |
| PL (1) | PL1828172T3 (enExample) |
| PT (1) | PT1828172E (enExample) |
| RU (1) | RU2007126761A (enExample) |
| TW (1) | TW200635921A (enExample) |
| WO (1) | WO2006063763A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0611695D0 (en) * | 2006-06-13 | 2006-07-26 | Novartis Ag | Organic compounds |
| TW200848019A (en) * | 2007-03-06 | 2008-12-16 | Wyeth Corp | Aryl sulfonamides useful for modulation of the progesterone receptor |
| EP2327693B9 (en) | 2007-12-14 | 2012-10-24 | Pulmagen Therapeutics (Asthma) Limited | Indoles and their therapeutic use |
| KR101276530B1 (ko) * | 2009-02-24 | 2013-06-18 | 머크 캐나다 인크. | Ｃｒｔｈ２ 수용체 길항제로서의 인돌 유도체 |
| WO2011079007A1 (en) | 2009-12-23 | 2011-06-30 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| BR112012024114B1 (pt) | 2010-03-22 | 2021-02-09 | Idorsia Pharmaceuticals Ltd | Compostos derivados de 3-(heteroarilamino)-1,2,3,4-tetrahidro-9h-carbazol, uso dos mesmos, e, composição farmacêutica |
| WO2011117184A1 (de) | 2010-03-24 | 2011-09-29 | Bayer Cropscience Ag | Fludioxonil-derivate |
| EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
| WO2012078210A1 (en) * | 2010-12-08 | 2012-06-14 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators and preparation thereof |
| JP5964945B2 (ja) | 2011-04-14 | 2016-08-03 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | ７−（ヘテロアリ−ル−アミノ）−６，７，８，９−テトラヒドロピリド［１，２−ａ］インド−ル酢酸誘導体及びプロスタグランジンＤ２受容体調節剤としてのそれらの使用 |
| WO2013088109A1 (en) | 2011-12-16 | 2013-06-20 | Oxagen Limited | Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
| ES2624379T3 (es) | 2011-12-21 | 2017-07-14 | Idorsia Pharmaceuticals Ltd | Derivados de heterociclilo y su uso como moduladores del receptor de prostaglandina D2 |
| WO2013155422A1 (en) * | 2012-04-12 | 2013-10-17 | Ironwood Pharmaceuticals, Inc. | Methods of treating alopecia and acne |
| US9169270B2 (en) | 2012-07-05 | 2015-10-27 | Actelion Pharmaceuticals Ltd. | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators |
| ES2461415B1 (es) * | 2012-10-16 | 2015-03-16 | Consejo Superior De Investigaciones Científicas (Csic) | Derivados funcionalizados e inmunorreactivos para el fungicida fludioxonil |
| CN103553990B (zh) * | 2013-11-08 | 2016-01-20 | 苏州诚和医药化学有限公司 | 用卤素卤化合成2－甲氧基－4－氨基－5－乙砜基苯甲酸甲酯的方法 |
| CN103588686B (zh) * | 2013-11-08 | 2016-01-20 | 苏州诚和医药化学有限公司 | 一种用卤素卤化制备2－甲氧基－4－氨基－5－乙砜基苯甲酸甲酯的方法 |
| CN103553991B (zh) * | 2013-11-08 | 2016-01-20 | 苏州诚和医药化学有限公司 | 一种制备2－甲氧基－4－氨基－5－乙砜基苯甲酸甲酯的方法 |
| TWI649321B (zh) | 2014-03-17 | 2019-02-01 | 瑞士商愛杜西亞製藥有限公司 | 氮雜吲哚乙酸衍生物及彼等作為前列腺素ｄ２受體調節劑之用途 |
| WO2015140701A1 (en) | 2014-03-18 | 2015-09-24 | Actelion Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| AU2016323262B2 (en) | 2015-09-15 | 2020-11-19 | Idorsia Pharmaceuticals Ltd | Crystalline forms |
| CN108164502B (zh) * | 2018-03-06 | 2021-04-13 | 苏州华一新能源科技有限公司 | 1,3-丙烷磺酸内酯的制备方法 |
| CN112602714B (zh) * | 2020-12-23 | 2021-11-16 | 华南农业大学 | 一类咯菌腈羧酸衍生物在用于植物维管组织靶向药剂中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0182737A3 (de) * | 1984-10-16 | 1986-10-08 | Ciba-Geigy Ag | 3-Phenylpyrrolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel |
| EP0386681A1 (de) * | 1989-03-08 | 1990-09-12 | Ciba-Geigy Ag | 3-Aryl-4-cyano-pyrrol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende mikrobiozide Mittel |
| US20050101657A1 (en) * | 2001-12-28 | 2005-05-12 | Takeda Chemical Industries Ltd. | Androgen receptor antagonists |
| JP4316232B2 (ja) * | 2001-12-28 | 2009-08-19 | 武田薬品工業株式会社 | アンドロゲン受容体拮抗剤 |
| TW200307542A (en) * | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0301010D0 (sv) * | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| GB0308466D0 (en) * | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| CA2568742A1 (en) * | 2004-05-29 | 2005-12-08 | 7Tm Pharma A/S | Substituted thiazoleacetic as crth2 ligands |
-
2004
- 2004-12-14 GB GBGB0427381.9A patent/GB0427381D0/en not_active Ceased
-
2005
- 2005-12-07 GT GT200500360A patent/GT200500360A/es unknown
- 2005-12-12 EP EP05815747A patent/EP1828172B1/en not_active Expired - Lifetime
- 2005-12-12 CN CN2005800416868A patent/CN101072773B/zh not_active Expired - Fee Related
- 2005-12-12 CA CA002587934A patent/CA2587934A1/en not_active Abandoned
- 2005-12-12 MX MX2007007098A patent/MX2007007098A/es active IP Right Grant
- 2005-12-12 PL PL05815747T patent/PL1828172T3/pl unknown
- 2005-12-12 AR ARP050105197A patent/AR052266A1/es not_active Application Discontinuation
- 2005-12-12 WO PCT/EP2005/013297 patent/WO2006063763A1/en not_active Ceased
- 2005-12-12 US US11/720,786 patent/US20100087432A1/en not_active Abandoned
- 2005-12-12 DE DE602005017935T patent/DE602005017935D1/de not_active Expired - Lifetime
- 2005-12-12 ES ES05815747T patent/ES2335519T3/es not_active Expired - Lifetime
- 2005-12-12 RU RU2007126761/04A patent/RU2007126761A/ru not_active Application Discontinuation
- 2005-12-12 AT AT05815747T patent/ATE449772T1/de not_active IP Right Cessation
- 2005-12-12 PE PE2005001434A patent/PE20060736A1/es not_active Application Discontinuation
- 2005-12-12 PT PT05815747T patent/PT1828172E/pt unknown
- 2005-12-12 KR KR1020077013302A patent/KR20070087605A/ko not_active Abandoned
- 2005-12-12 BR BRPI0518607-2A patent/BRPI0518607A2/pt not_active IP Right Cessation
- 2005-12-12 AU AU2005315881A patent/AU2005315881C1/en not_active Ceased
- 2005-12-12 JP JP2007545917A patent/JP2008523130A/ja active Pending
- 2005-12-13 TW TW094143970A patent/TW200635921A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070087605A (ko) | 2007-08-28 |
| AU2005315881A1 (en) | 2006-06-22 |
| AU2005315881B2 (en) | 2009-09-24 |
| PT1828172E (pt) | 2010-02-17 |
| ATE449772T1 (de) | 2009-12-15 |
| CN101072773B (zh) | 2011-01-19 |
| CA2587934A1 (en) | 2006-06-22 |
| TW200635921A (en) | 2006-10-16 |
| JP2008523130A (ja) | 2008-07-03 |
| PL1828172T3 (pl) | 2010-05-31 |
| MX2007007098A (es) | 2007-06-22 |
| DE602005017935D1 (de) | 2010-01-07 |
| US20100087432A1 (en) | 2010-04-08 |
| WO2006063763A1 (en) | 2006-06-22 |
| CN101072773A (zh) | 2007-11-14 |
| EP1828172A1 (en) | 2007-09-05 |
| EP1828172B1 (en) | 2009-11-25 |
| PE20060736A1 (es) | 2006-09-08 |
| BRPI0518607A2 (pt) | 2008-11-25 |
| AR052266A1 (es) | 2007-03-07 |
| GB0427381D0 (en) | 2005-01-19 |
| ES2335519T3 (es) | 2010-03-29 |
| GT200500360A (es) | 2006-08-07 |
| AU2005315881C1 (en) | 2010-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007126761A (ru) | ПРОИЗВОДНЫЕ ПИРРОЛА, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К РЕЦЕПТОРУ CRTh2 | |
| RU2008152180A (ru) | ПРОИЗВОДНЫЕ ПИРРОЛА, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ CRTh2 РЕЦЕПТОРА | |
| RU2004119438A (ru) | Производные бензотиазола | |
| CA2536136A1 (en) | Aryloxy and arylalkyleneoxy substituted imidazoquinolines | |
| RU2001132139A (ru) | Имидазохинолины с сульфонамидными или сульфамидным замещением | |
| RU2006105717A (ru) | Производные пиперазина и их применение в качестве терапевтических агентов | |
| RU2007106180A (ru) | Производные индола, индазола или индолина | |
| RU2004136977A (ru) | Производные пиридазин-3(2h)-она в качестве ингибиторов фосфодиэстеразы 4 (pde4) | |
| RU2002122105A (ru) | Производное бензимидазола | |
| RU2003137578A (ru) | Производные ароматических дикарбоновых кислот | |
| RU2002123350A (ru) | Дипептиднитрильные ингибиторы катепсина К | |
| RU2007147420A (ru) | Органические соединения для лечения воспалительных или аллергических состояний | |
| RU2003121236A (ru) | Арилированные амиды фуран- и тиофенкарбоновых кислот с блокирующим калиевый канал действием | |
| RU2008142600A (ru) | Органическое соединение | |
| JP2005532371A5 (enExample) | ||
| CA2805206A1 (fr) | Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide | |
| RU2005102002A (ru) | Новые производные тетрагидропиридина | |
| RU2012106822A (ru) | Индольное производное или его фармацевтически приемлемая соль | |
| RU2009119421A (ru) | Производные 2-фенил-6-аминокарбонилпиримидина и их применение в качестве антагонистов тромбоцитарного рецептора адф (p2y12 рецептора) | |
| RU2005123401A (ru) | Ароматические соединения как противовоспалительные, иммуномодулирующие и антипролиферативные средства | |
| JP2004507531A5 (enExample) | ||
| RU2005137571A (ru) | Новые производные диазабициклононена | |
| JP6247004B2 (ja) | 帯状疱疹関連通の急性期疼痛の予防又は治療剤 | |
| RU2008127439A (ru) | Арилуксусная кислота и ее сложно-эфирные производные и их применение в качестве противовоспалительного средства | |
| NO20071244L (no) | Anvendelse av cellespesifikke konjugater for behandling av inflammasjonssykdommer i gastrointestinaltrakten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20110825 |